Page 6 - Phasei Ii News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Grifols to launch trial for potential COVID-19 therapy The subcutaneously administered immunoglobulin, if successful, would provide rapid immunity against the virus behind the deadly global pandemic. Biopharmaceutical firm Grifols, which specializes in development of therapies harnessing plasma-derived proteins, has announced it is kicking off a clinical trial in Spain to test the viability of a potential COVID-19 treatment. Based on the company’s immunoglobulin Gamunex-C and containing polyclonal antibodies, the drug at the center of the study reportedly has the...

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment. Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments in patients suffering respiratory distress as a result of COVID-19 infection. Inhaled Ampion specif...

Florida doctor pleads guilty to clinical trial data fraud A Miami physician has owned up to falsifying research data and patient participation figures for a pediatric asthma trial conducted from 2013 to 2016. Yvelice Villaman Bencosme of Miami, Florida, has entered a guilty plea in US District Court for the Southern District of Florida, in response to one count of conspiracy to commit wire fraud. Bencosme (who served as primary investigator for clinical purportedly conducted at the medical clinic Unlimited Medical Research in Miami) admitted that from approximately...

Repurposing existing drugs accelerates discovery: XenoTech Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO. Pharmaceutical companies and their development partners are continually looking for safe, efficient ways to accelerate delivery of therapies to the patients that need them—especially in the face of the COVID-19 pandemic. One appealing path to new treatments is to explore ways to repurpose a drug intended for one indication and repurpose it for another. ...